Haemonetics Corporation (HAE)
| Market Cap | 4.11B +58.6% |
| Revenue (ttm) | 1.35B +0.4% |
| Net Income | 96.29M -41.1% |
| EPS | 2.06 -37.2% |
| Shares Out | 45.50M |
| PE Ratio | 43.84 |
| Forward PE | 16.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 464,972 |
| Open | 90.09 |
| Previous Close | 90.80 |
| Day's Range | 89.06 - 91.36 |
| 52-Week Range | 47.32 - 92.25 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 96.90 (+7.35%) |
| Earnings Date | Aug 6, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management syst... [Read more]
Financial Performance
In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $96.9, which is an increase of 7.35% from the latest price.
News
Haemonetics price target raised to $100 from $93 at BofA
BofA raised the firm’s price target on Haemonetics (HAE) to $100 from $93 and keeps a Buy rating on the shares after the firm hosted CEO Chris Simon for a…
Haemonetics price target raised to $105 from $90 at Raymond James
Raymond James raised the firm’s price target on Haemonetics (HAE) to $105 from $90 and keeps an Outperform rating on the shares.
Haemonetics price target raised to $96 from $88 at Baird
Baird raised the firm’s price target on Haemonetics (HAE) to $96 from $88 and keeps an Outperform rating on the shares. The firm updated its model following bigger than expected…
Haemonetics price target raised to $95 from $89 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $95 from $89 and keeps an Outperform rating on the shares. The firm cites the company’s Q1 beat for the…
Haemonetics price target raised to $92 from $79 at Citi
Citi raised the firm’s price target on Haemonetics (HAE) to $92 from $79 and keeps a Neutral rating on the shares.
Haemonetics Earnings Call Transcript: Q1 2027
Revenue grew 6% year-over-year to $339 million, with all core platforms contributing to profitable growth and adjusted EPS up 4%. Guidance for FY27 was raised, reflecting strong plasma and MedSurg performance, robust cash flow, and continued innovation, while maintaining a disciplined outlook amid cost pressures.
Haemonetics Slides: Q1 2027
Haemonetics has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Haemonetics Earnings release: Q1 2027
Haemonetics released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Haemonetics Quarterly report: Q1 2027
Haemonetics has published its Q1 2027 quarterly earnings report on August 6, 2026.
Haemonetics reports Q1 adjusted EPS $1.14, consensus $1.08
Reports Q1 revenue $339.38M, consensus $327.89M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies mome...
Haemonetics raises FY27 adjusted EPS view to up 5%-8% from up 4%-7%
Raises FY27 revenue view to up 5%-8% from up 4%-7%.
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal...
Haemonetics’ Vascade MVP system shows efficacy in electrophysiology study
Haemonetics (HAE) announced publication of a study providing new evidence supporting the safety and efficacy of Haemonetics’ Vascade MVP XL venous vascular closure system in large-bore sheath procedur...
New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
BOSTON, Aug. 3, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ann...
Haemonetics price target raised to $93 from $80 at BofA
BofA raised the firm’s price target on Haemonetics (HAE) to $93 from $80 and keeps a Buy rating on the shares, citing Plasma and Hospital upside and higher peer multiples.
Martin Madaus Elected to Haemonetics Board of Directors
BOSTON, July 28, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, annou...
Haemonetics price target raised to $90 from $85 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Haemonetics (HAE) to $90 from $85 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, Augus...
Citi adds ‘downside 90-day catalyst watch’ on Haemonetics
Citi analyst Joanne Wuensch is adding a “downside 90-day catalyst watch” on Haemonetics (HAE), raised the firm’s price target on shares to $79 from $70 and keeps a Neutral rating.
Haemonetics management to meet virtually with BTIG
Virtual Meeting to be held on June 24 hosted by BTIG.
Haemonetics price target raised to $85 from $70 at Mizuho
Mizuho raised the firm’s price target on Haemonetics (HAE) to $85 from $70 and keeps an Outperform rating on the shares. The firm attributes the recent rally in the shares…
Pharvaris Announces Annual General Meeting of Shareholders
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Haemonetics Proxy statement: Proxy filing
Haemonetics filed a proxy statement on June 9, 2026, providing details for shareholder voting and corporate governance matters.
Haemonetics Proxy statement: Proxy filing
Haemonetics filed a proxy statement on June 9, 2026, providing details for shareholder voting and corporate governance matters.
Haemonetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management highlighted strong execution on a four-year transformation plan, surpassing growth and earnings targets, and set conservative FY 2027 guidance of 3%-6% organic growth. Key drivers include innovation, share gains, and operational leverage, with upside potential from faster technology adoption and market stabilization.